Ann: FDA Fast Track Designation Granted for VAXINIA Trial Program, page-384

Hi Wedgeman7, That is a great question and an option I hadn’t really considered. I think there are many possibilities with IMU which makes it an unusual beast. I think what you are suggesting is very plausible for a couple of reasons and maybe not just related to IMU. Given where the Australian biotech sector is at it might be well worth BP having and growing such a presence in Australia. There is a significant amount of talent in this country developing some great assets. I think that the team at IMU could help move some of those assets along, I know I look at some of my other biotech holdings and think only if LC could be cloned. I think it is really something that the sector in Australia is now mature enough for and I would think that if BP had some foresight to expand a developmental base in Australia they would do very well. I think there are also very good support structures now for clinical trials in Australia and access the Asian region. This link has some interesting commentary in it which provides some perspective on what BP think of the development opportunity in Australia. https://treasury.gov.au/sites/default/files/2022-03/258735_pfizer_australia.pdf